DFX Intelligence
Private Credit Intelligence
The capital structure graph behind private markets. Who lent, to whom, under which sponsor, through which facility, how large the piece was, when it matures and what changed, with a filing behind every number. A BDC piece is that BDC's piece, a sum of pieces is a lower bound, and a sponsor is named with the evidence that names it.
Borrowers
48 borrower groups currently held
A borrower group is every spelling of one credit agreement's borrower across the BDCs that hold it (Icefall Parent, Icefall Topco and Icefall Bidco are one). Grade A and B groups are listed; a short one-word stem (grade C) is kept apart and never merged across filers. Principal is the sum of BDC pieces and is a lower bound.
| Borrower | Sponsor | BDCs | Principal held | On cost | Next maturity | First seen |
|---|---|---|---|---|---|---|
| Dyne Therapeutics, Inc Drug Discovery & Development | unattributed | 1 | at least $142M | 102c | Jul 1, 2030 | Jun 30, 2025 |
| Phathom Pharmaceuticals, Inc Drug Discovery & Development | Novaquest Capital Management, L.L.C. carried | 1 | at least $133M | 101c | Feb 1, 2029 | Dec 31, 2022 |
| Axsome Therapeutics, Inc Drug Discovery & Development | unattributed | 3 | at least $114M | 101c | May 8, 2030 | Dec 31, 2022 |
| Corium, Inc Drug Discovery & Development · grade B | unattributed | 1 | at least $86.9M | 101c | Sep 1, 2026 | Dec 31, 2022 |
| Heron Therapeutics, Inc Drug Discovery & Development | unattributed | 1 | at least $80.8M | 97c | Sep 1, 2030 | Sep 30, 2023 |
| Arcus Biosciences, Inc Drug Discovery & Development | unattributed | 1 | at least $76.5M | 105c | Sep 1, 2030 | Sep 30, 2024 |
| X4 Pharmaceuticals, Inc Drug Discovery & Development | unattributed | 1 | at least $75.0M | 100c | Jul 1, 2027 | Dec 31, 2022 |
| Genetix Biotherapeutics Inc Drug Discovery & Development | SK Capital Partners carried | 1 | at least $67.1M | 100c | Apr 1, 2029 | Sep 30, 2025 |
| Replimune Group, Inc Drug Discovery & Development | Omega Fund Management, LLC carried | 1 | at least $57.3M | 100c | Oct 1, 2027 | Dec 31, 2022 |
| Braeburn, Inc Drug Discovery & Development | unattributed | 1 | at least $53.7M | 102c | Oct 1, 2028 | Sep 30, 2023 |
| MoonLake Immunotherapeutics Drug Discovery & Development | unattributed | 1 | at least $46.0M | 101c | Apr 1, 2030 | Mar 31, 2025 |
| COMPASS Pathways plc Drug Discovery & Development | unattributed | 1 | at least $42.5M | 102c | Jan 1, 2031 | Jun 30, 2023 |
| Lexicon Pharmaceuticals, Inc Drug Discovery & Development | unattributed | 1 | at least $39.9M | 100c | May 1, 2030 | Jun 30, 2026 |
| Disc Medicine, Inc Drug Discovery & Development | Foresite Capital carried | 1 | at least $35.0M | 104c | Dec 1, 2029 | Dec 31, 2024 |
| Maze Therapeutics, Inc Drug Discovery & Development | unattributed | 1 | at least $28.0M | 101c | Feb 1, 2031 | Dec 31, 2025 |
| uniQure B.V Drug Discovery & Development · grade B | unattributed | 1 | at least $27.5M | 103c | Oct 1, 2030 | Dec 31, 2022 |
| Savara, Inc Drug Discovery & Development · grade B | unattributed | 1 | at least $21.4M | 101c | Apr 1, 2030 | Dec 31, 2022 |
| Tenpoint Therapeutics Limited Drug Discovery & Development | unattributed | 1 | at least $18.8M | 98c | Oct 1, 2029 | Mar 31, 2026 |
| Altimmune, Inc Drug Discovery & Development | Viking Global Investors LP carried | 1 | at least $17.5M | 100c | Jun 1, 2029 | Jun 30, 2025 |
| enGene Therapeutics Inc Drug Discovery & Development | unattributed | 1 | at least $17.5M | 100c | Jan 1, 2030 | Jun 30, 2026 |
| enGene, Inc Drug Discovery & Development · grade B | unattributed | 1 | at least $17.5M | 103c | Jan 1, 2030 | Dec 31, 2022 |
| Beren Therapeutics P.B.C Drug Discovery & Development | Alpha Wave Global, LP carried | 1 | at least $17.3M | 99c | Oct 1, 2029 | Dec 31, 2025 |
| 4D Molecular Therapeutics, Inc Drug Discovery & Development | Viking Global Investors LP carried | 1 | at least $15.2M | 100c | Jun 1, 2031 | Dec 31, 2025 |
| Aldeyra Therapeutics, Inc Drug Discovery & Development | unattributed | 1 | at least $15.0M | 100c | Apr 1, 2026 | Dec 31, 2022 |
| SynOx Therapeutics Limited Drug Discovery & Development | unattributed | 1 | at least $10.5M | 101c | May 1, 2028 | Jun 30, 2024 |
| Alector, Inc Drug Discovery & Development · grade B | unattributed | 1 | at least $7.0M | 102c | Dec 1, 2028 | Dec 31, 2024 |
| Kura Oncology, Inc Drug Discovery & Development | Avoro Capital Advisors LLC carried | 1 | at least $5.5M | 102c | Nov 1, 2027 | Dec 31, 2022 |
| NorthSea Therapeutics Drug Discovery & Development | unattributed | 1 | at least $473,000 | 100c | Jun 1, 2027 | Dec 31, 2022 |
| Avalo Therapeutics, Inc Drug Discovery & Development | Orbimed Advisors LLC carried | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Bicycle Therapeutics PLC Drug Discovery & Development | SR One Capital Management, LP carried | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Cellarity, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Century Therapeutics, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Cuervo, Inc Drug Discovery & Development · grade B | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2023 |
| Curevo, Inc Drug Discovery & Development · grade B | unattributed | 1 | unknown | n/a | unstated | Jun 30, 2023 |
| Daré Bioscience, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2025 |
| Dare Biosciences, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Dynavax Technologies Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Hibercell, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Madrigal Pharmaceutical, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Madrigal Pharmaceuticals, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Sep 30, 2025 |
| Rafael Holdings, Inc Drug Discovery & Development · grade B | unattributed | 1 | unknown | n/a | unstated | Mar 31, 2025 |
| Redshift Bioanalytics, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Rocket Pharmaceuticals, Ltd Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Scynexis, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| TG Therapeutics, Inc Drug Discovery & Development | unattributed | 8 | unknown | n/a | unstated | Dec 31, 2022 |
| Valo Health, LLC Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
| Verge Analytics, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Sep 30, 2023 |
| Viridian Therapeutics, Inc Drug Discovery & Development | unattributed | 1 | unknown | n/a | unstated | Dec 31, 2022 |
Page 1 of 1
Principal and marks are the filers' figures at each BDC's latest quarter end, summed. Maturity is the filer's tagged date or the date written into the identifier; a BDC that tags neither leaves it unstated.